news
NICE recommends five new therapies
27 January 2016 | By Victoria White
NICE has published its final recommendations on whether six different drug treatments should be routinely funded by the NHS...
List view / Grid view
Bayer HealthCare
news
NICE recommends Xofigo (radium-223) for prostate cancer
19 November 2015 | By Victoria White
NICE’s FAD coincides with a period of great uncertainty with the Cancer Drugs Fund deliberating again whether to remove radium-223 from the list...
news
EC approves Eylea for myopic choroidal neovascularisation
30 October 2015 | By Victoria White
Bayer plans for an immediate introduction of Eylea to the market with Germany being one of the first launch countries in Europe...
news
Isis Pharmaceuticals initiates Phase 2 study of ISIS-FXI Rx in ESRD
30 October 2015 | By Victoria White
The Phase 2 study is intended to further characterise the profile of ISIS-FXI Rx and will provide essential data for Bayer's future clinical development programme for ISIS-FXI Rx...
news
Regorafenib now available on NHS Wales for treatment of advanced GIST
24 July 2015 | By Victoria White
Regorafenib has been recommended for use on NHS Wales as a third-line treatment for patients with advanced gastrointestinal stromal tumours (GIST).
news
EU approves Gadovist for use in paediatric patients less than 2 years of age
14 July 2015 | By Victoria White
Bayer's Gadovist has received a label extension in the EU for diagnostic use with MRI or MRA in paediatric patients less than 2 years of age...
news
SMC accepts sorafenib for use in Scotland
13 July 2015 | By Victoria White
The SMC has announced that sorafenib has been accepted for use within NHS Scotland for the treatment of patients with thyroid carcinoma...
news
Studies confirm regorafenib benefit in pre-treated metastatic colorectal cancer
3 July 2015 | By Victoria White
The Phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC)...
news
Bayer to sell its Diabetes Care business to Panasonic Healthcare Holdings Co. Ltd.
10 June 2015 | By Victoria White
Bayer has entered into a definitive agreement to sell its Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd., for EUR 1,022 million...
news
New clinical research programme launched for the prevention and treatment of blood clots in patients with cancer
29 May 2015 | By VIctoria White
Janssen and Bayer have launched a clinical research programme evaluating rivaroxaban for the prevention and treatment of blood clots in patients with cancer...
news
FDA approves Avelox as a treatment for patients with plague
11 May 2015 | By Victoria White
The FDA has approved Avelox in the US to treat patients with plague, including pneumonic plague and septicemic plague...
news
Evotec receives milestone as part of its multi-target alliance with Bayer HealthCare
13 October 2014 | By Evotec
Evotec AG announced that its multi-target collaboration with Bayer HealthCare has reached an important milestone for the transition of a molecule into pre-clinical development for the treatment of endometriosis...
news
Bayer and Onyx report Phase 3 study results of NEXAVAR® (sorafenib) as adjuvant treatment for patients with liver cancer who have undergone surgery or local ablation
11 March 2014 | By Amgen
Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma...
news
U.S. FDA Approves NEXAVAR® (sorafenib) for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment
22 November 2013 | By Amgen
First and only FDA-approved treatment option for patients with this type of thyroid cancer...
news
FT Global Pharmaceutical and Biotechnology Conference
6 August 2013 | By Financial Times
3 – 4 December 2013, The InterContinental Park Lane, London...
